vs
Side-by-side financial comparison of Caledonia Mining Corp Plc (CMCL) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $46.9M, roughly 1.5× Caledonia Mining Corp Plc). Caledonia Mining Corp Plc runs the higher net margin — 7.0% vs -49.0%, a 56.0% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 13.8%).
Hochschild Mining plc is a leading British-based silver and gold mining business operating in North, Central, and South America. It is headquartered in Lima, Peru, with a corporate office in London, is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index. The main shareholder is the Peruvian businessman Eduardo Hochschild.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
CMCL vs VRDN — Head-to-Head
Income Statement — Q3 FY2024 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $46.9M | $70.6M |
| Net Profit | $3.3M | $-34.6M |
| Gross Margin | 41.2% | — |
| Operating Margin | 18.6% | -56.7% |
| Net Margin | 7.0% | -49.0% |
| Revenue YoY | 13.8% | 81958.1% |
| Net Profit YoY | -33.3% | 54.9% |
| EPS (diluted) | $0.13 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $70.6M | ||
| Q3 24 | $46.9M | — | ||
| Q2 24 | $50.1M | — | ||
| Q1 24 | $38.5M | — | ||
| Q4 23 | $38.7M | — | ||
| Q3 23 | $41.2M | — | ||
| Q2 23 | $37.0M | — | ||
| Q1 23 | $29.4M | — |
| Q3 25 | — | $-34.6M | ||
| Q3 24 | $3.3M | — | ||
| Q2 24 | $10.2M | — | ||
| Q1 24 | $2.1M | — | ||
| Q4 23 | $-2.6M | — | ||
| Q3 23 | $4.9M | — | ||
| Q2 23 | $-2.5M | — | ||
| Q1 23 | $-4.6M | — |
| Q3 25 | — | — | ||
| Q3 24 | 41.2% | — | ||
| Q2 24 | 45.8% | — | ||
| Q1 24 | 35.9% | — | ||
| Q4 23 | 27.3% | — | ||
| Q3 23 | 34.3% | — | ||
| Q2 23 | 29.5% | — | ||
| Q1 23 | 19.9% | — |
| Q3 25 | — | -56.7% | ||
| Q3 24 | 18.6% | — | ||
| Q2 24 | 32.2% | — | ||
| Q1 24 | 13.8% | — | ||
| Q4 23 | 6.0% | — | ||
| Q3 23 | 22.4% | — | ||
| Q2 23 | 2.5% | — | ||
| Q1 23 | -5.1% | — |
| Q3 25 | — | -49.0% | ||
| Q3 24 | 7.0% | — | ||
| Q2 24 | 20.3% | — | ||
| Q1 24 | 5.4% | — | ||
| Q4 23 | -6.7% | — | ||
| Q3 23 | 12.0% | — | ||
| Q2 23 | -6.8% | — | ||
| Q1 23 | -15.8% | — |
| Q3 25 | — | — | ||
| Q3 24 | $0.13 | — | ||
| Q2 24 | $0.42 | — | ||
| Q1 24 | $0.07 | — | ||
| Q4 23 | $-0.19 | — | ||
| Q3 23 | $0.21 | — | ||
| Q2 23 | $-0.14 | — | ||
| Q1 23 | $-0.32 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.2M | $490.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $231.0M | $503.0M |
| Total Assets | $339.7M | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $490.9M | ||
| Q3 24 | $7.2M | — | ||
| Q2 24 | $15.4M | — | ||
| Q1 24 | $1.8M | — | ||
| Q4 23 | $6.7M | — | ||
| Q3 23 | $10.8M | — | ||
| Q2 23 | $12.8M | — | ||
| Q1 23 | $19.0M | — |
| Q3 25 | — | $503.0M | ||
| Q3 24 | $231.0M | — | ||
| Q2 24 | $231.1M | — | ||
| Q1 24 | $220.3M | — | ||
| Q4 23 | $224.2M | — | ||
| Q3 23 | $226.6M | — | ||
| Q2 23 | $224.3M | — | ||
| Q1 23 | $223.4M | — |
| Q3 25 | — | $577.1M | ||
| Q3 24 | $339.7M | — | ||
| Q2 24 | $338.5M | — | ||
| Q1 24 | $321.8M | — | ||
| Q4 23 | $328.3M | — | ||
| Q3 23 | $320.3M | — | ||
| Q2 23 | $313.9M | — | ||
| Q1 23 | $320.0M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.6M | $-84.6M |
| Free Cash FlowOCF − Capex | — | $-84.7M |
| FCF MarginFCF / Revenue | — | -120.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | 1.40× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-84.6M | ||
| Q3 24 | $4.6M | — | ||
| Q2 24 | $19.1M | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | $14.5M | — | ||
| Q2 23 | $-2.2M | — | ||
| Q1 23 | — | — |
| Q3 25 | — | $-84.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
| Q3 25 | — | -120.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
| Q3 25 | — | 0.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
| Q3 25 | — | — | ||
| Q3 24 | 1.40× | — | ||
| Q2 24 | 1.87× | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | 2.94× | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
